Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities

Morgan, Elizabeth A.; Sweeney, Maranna; Tomoka, Tamiwe; Kopp, Nadja; Gusenleitner, Daniel; Redd, Robert A.; Carey, Christopher D.; Masamba, Leo; Kamiza, Steve; Pinkus, Geraldine S.; Neuberg, Donna; Rodig, Scott J.; Milner, Danny A.; Weinstock, David M.

doi:10.1182/bloodadvances.2016000026

Cited by 8 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proportion of the DLBCL, NOS GCB type was more recurrent than the non-GCB type. This data is somewhat different from several reports conducted on other sub-Saharan African, Asian, and Western cohorts, where a higher prevalence of the [20,[32][33][34][35]. The co-expression of c-MYC and BCL2 proteins (double expressor) was seen in just two cases of the DLBCL, NOS.…”

Section: Discussioncontrasting

confidence: 94%

Distinct pattern of lymphoid neoplasms characterizations according to the WHO classification (2016) and prevalence of associated Epstein–Barr virus infection in Nigeria population

Uzoma

Taiwo

Granai

et al. 2021

Infect Agents Cancer

View full text Add to dashboard Cite

Background The present study aimed to classify lymphoid neoplasms according to the latest World Health Organization (WHO) classification and outlining the distribution in Nigeria of different entities. Additionally, the study describes the prevalence of lymphoid neoplasms associated with Epstein-Barr virus (EBV) infection in the Nigerian population. Methods We collected 152 formalin-fixed paraffin-embedded (FFPE) tissues diagnosed as lymphoma from 2008 to 2018, coming from three different institutions located within three geopolitical zone in Nigeria. These institutions included the University College Hospital (UCH), Ibadan, Oyo State, the Enugu State University of Science and Technology Teaching Hospital (ESUTH), Enugu, Enugu State, and the Meena Histopathology and Cytology Laboratory (MHCL), Jos, Plateau State. Results From the total 152 cases retrieved, 50 were excluded due to insufficient tissue materials or inconclusive antigen reactivity. We confirmed 66 (64.7%) cases as lymphomas out of the remaining 102 FFPE with a male to female ratio of 2:1 and a mean age of 44.4 years. Ten entities were identified, and of these, chronic lymphocytic leukemia (CLL) was the most prevalent category (34.8%). For the diffuse large B-cell lymphomas not otherwise specified (DLBCL, NOS), the germinal centre B–cell type was the most common (71.4%). Ten lymphoma cases (15.2%) were positive for Epstein-Barr virus (EBV), most of which were Hodgkin lymphoma (HL). CLL was common in the Hausa ethnic group, HL in the Yoruba ethnic group, while the Igbo ethnic group had an equal distribution of CLL, HL, and DLBCL diagnosis. Conclusion Although the distribution of lymphomas in Nigeria shares some similarities with those of other countries, we described distinct features of some subtypes of lymphomas. Also, the study underscores the need for a more precise diagnosis and classification of lymphoid neoplasms in Nigeria using the latest WHO classification.

show abstract

Section: Discussioncontrasting

confidence: 94%

Distinct pattern of lymphoid neoplasms characterizations according to the WHO classification (2016) and prevalence of associated Epstein–Barr virus infection in Nigeria population

Uzoma

Taiwo

Granai

et al. 2021

Infect Agents Cancer

View full text Add to dashboard Cite

show abstract

“…Prognostic and predictive biomarkers Deceased: Kristy L. Richards of DLBCL that are widely accepted in resource-rich regions and incorporated into the current classification schemes have not been effectively studied in resourcelimited settings [13]. When such efforts have been undertaken for lymphoma in SSA, they have been limited by incomplete ascertainment of HIV status, clinical outcomes, and nonstandardized treatment [14]. Whether or not these markers are valid in settings characterized by the distinct genetic, environmental, and socioeconomic pressures of SSA remains uncertain.…”

Section: Introductionmentioning

confidence: 99%

Identifying transcriptional profiles and evaluating prognostic biomarkers of HIV-associated diffuse large B-cell lymphoma from Malawi

et al. 2020

Self Cite

View full text Add to dashboard Cite

Lymphoma incidence in sub-Saharan Africa (SSA) is increasing due to HIV and population aging. Diffuse Large B-cell lymphoma (DLBCL), the most common lymphoma in SSA and worldwide, is highly associated with HIV, but molecular studies of HIV-associated DLBCL are scarce globally. We describe profiling of DLBCL from Malawi, aiming to elucidate tumor biology and identify clinically meaningful biomarkers specifically for SSA. Between June 1, 2013 and June 1, 2016, 59 cases of DLBCL (32 HIV+/27 HIV−) enrolled in the Kamuzu Central Hospital Lymphoma Study were characterized, of which 54 (92%) were negative for Epstein-Barr virus. Gene expression profiling (GEP) by whole transcriptome sequencing was performed on the first 36 cases (22 HIV+/14 HIV−). Immunohistochemistry (IHC) and GEP results were compared with published data and correlated to clinical outcome and pathologic features. Unsupervised clustering strongly segregated DLBCL by HIV status (p = 0.0003, Chi-squared test), indicating a marked contribution of HIV to expression phenotype. Pathway analysis identified that HIV-associated tumors were enriched in hypoxia, oxidative stress, and metabolism related gene expression patterns. Cell-of-origin subtype, determined by sequencing and IHC, did not associate with differences in overall survival (OS), while Ki-67 proliferation index ≥80% was associated with inferior OS in HIV+ DLBCL only (p = 0.03) and cMYC/BCL2 co-expression by IHC was negatively prognostic across the entire cohort (p = 0.01). This study provides among the first molecular characterizations of DLBCL from SSA, demonstrates marked gene expression differences by HIV status, and identifies genomic and immunophenotypic characteristics that can inform future basic and clinical investigations.

show abstract

“…24 Targeted therapies such as these may eventually become attractive alternatives to systemic chemotherapy in resource-limited settings. 25 In pediatric patients, systematic literature review has highlighted a better initial response to therapy compared with adults, with a better overall survival rate and lower rates of relapse. 26 Younger age and isolated cutaneous disease are reported to be associated with better prognosis.…”

Section: Discussionmentioning

confidence: 99%

Blastic Plasmacytoid Dendritic Cell Neoplasm: First Case Report From Rwanda and Review of the Literature

Ruhangaza¹,

Mugabe²,

Kigonya³

et al. 2019

JGO

Self Cite

View full text Add to dashboard Cite

Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities

Abstract: Key Points• NHL subclassification is lacking in Malawi due to resource constraints yet is critical for directing therapy.• Targeted gene expression profiling facilitates objective assessment and segregation of biologically defined subsets of NHL from Malawi.

Cited by 8 publications

References 37 publications

Distinct pattern of lymphoid neoplasms characterizations according to the WHO classification (2016) and prevalence of associated Epstein–Barr virus infection in Nigeria population

Distinct pattern of lymphoid neoplasms characterizations according to the WHO classification (2016) and prevalence of associated Epstein–Barr virus infection in Nigeria population

Identifying transcriptional profiles and evaluating prognostic biomarkers of HIV-associated diffuse large B-cell lymphoma from Malawi

Blastic Plasmacytoid Dendritic Cell Neoplasm: First Case Report From Rwanda and Review of the Literature

Contact Info

Product

Resources

About